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In recent years, a significant number of studies have investigated the preventive role of vitamin D in a 
number of different neoplasms. In this study, we analyze various components of the vitamin D signaling 
pathways in the human uveal tract and uveal melanoma, including analysis of the expression of vitamin 
D receptors (VDR), the activating and inactivating hydroxylases, respectively, CYP27B1 and CYP24A1, 
and the retinoic acid-related orphan receptors (ROR) α (RoRα) and γ (RoRγ) in these tissues. We 
further analyzed the expression of VDR, CYP27B1, CYP24A1, and ROR in relation to melanin levels, 
clinical stage and prognosis. Our study indicated that the uveal melanoma melanin level inversely 
correlated with VDR expression. We further showed that vitamin D is metabolized in uveal melanoma. 
This is significant because until now there has been no paper published, that would describe presence 
of VDR, hydroxylases CYP27B1 and CYP24A1, and RORα and RoRγ in the human uveal tract and uveal 
melanomas. The outcomes of our research can contribute to the development of new diagnostic and 
therapeutic methods in uveal tract disorders, especially in uveal melanoma. The presented associations 
between vitamin D signaling elements and uveal melanoma in comparison to uveal tract encourage 
future clinical research with larger patients’ population.
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Melanomas developing from ocular tissues make up to 5% of all melanomas. Among them, 5% are conjunctival 
melanomas, 85% uveal melanomas, and 10% are lesions occurring in other ocular structures1.
Uveal melanoma is the most frequent primary intraocular tumor in adults. The most frequent location in 
uveal melanomas is the choroid (90%), less frequent – the ciliary body (6%), while the iris is the least frequent 
location (4%)2. The prevalence varies depending on the population studied: in the USA, this is 5.1 new cases per 1 
million inhabitants per year3,4. In Europe, the prevalence of this tumor is determined by latitude: in the countries 
of Southern Europe (Italy, Spain) these are 2 cases per 1 million per year, whilst in the Northern part of the conti-
nent (Norway, Denmark) – 84,5. In Asia and Africa, the prevalence is assessed to be about 0.2 to 0.3 new cases per 
1 million per year3,6. This type of cancer is the most frequent among Caucasians (98%)3,7. Uveal melanoma may 
occur at any age, yet it is quite rare among children and young adults8. The incidence increases with age, reaching 
a constant level at the age of 75, whereas the average age when this cancer is diagnosed ranges from 59 to 622–4.
Thanks to the current methods of uveal melanoma treatment, the rate of positive effects of local treatment is 
about 76–100%9,10. Unfortunately, there are still no effective treatment methods which would allow to cure the 
disease completely or to prolong significantly the survival of the patients in whose case tumor spread occurred. 
An average survival period from the moment of diagnosing distant metastases is 4–15 months, while only 
10–15% patients survive 1-year11,12. The 5-year mortality in patients with uveal melanoma is 31%, while the 
15-year mortality is 45%13. This brings the necessity of a farther search for new mechanisms which affect the 
oncogenesis of this tumor, its metastases and also for the prognostic markers allowing better assessment of disease 
outcome and facilitating the selection of the proper treatment and follow-up pattern.
Within the last few years, the number of studies concerning the function of vitamin D and its effect on human 
disease has significantly increased. Vitamin D is a prohormone that is produced in the skin through photochem-
ical transformation of 7-dehydrocholesterol upon exposure to ultraviolet radiation B (UVB)14–19. Vitamin D is 
activated through sequential hydroxylations at C25 (by CYP27A1 and/or CYP2R) with following hydroxylation at 
C12 by CYP27B1 and inactivated by CYP24A1 through hydroxylation at C24 with further shortening at the side 
chain to produce calcitroic acid14–17. Via its interaction with the vitamin D receptor (VDR) active form of vitamin 
D3, 1,25-dihidroxyvitaminD3 (1,25(OH)2D3) regulates the transcription of many genes16,17,20. In addition to its 
role in the regulation of calcium and phosphate metabolism, vitamin D has many other functions that include 
the regulation of inflammation and immune functions (inhibiting autoimmune processes), stimulation of cell 
differentiation and maturation, inhibition of cell proliferation, regulation of endocrine functions (e.g., insulin 
secretion). In addition, It has been reported to stimulate neuron regeneration, increase muscle mass and strength, 
stimulate hepatic cell regeneration, inhibit the development of depression and schizophrenia, affect the circula-
tory system through renin-angiotensin-aldosterone system, and decrease the risk of oral decay21–23.
Another important functions of active form of vitamin D are its anti-tumor effects, antimutagenic properties (e.g. 
protection against the effect of free radicals) and the regulation of tumor proliferation, apoptosis, and angiogenesis24,25.
It was shown that vitamin D deficiency or dysregulated vitamin D signaling can play an important role in 
oncogenesis, clinical advancement and prognosis in such neoplasms as cutaneous melanomas, bladder, breast, 
lung, ovarian, pancreatic, thyroid, prostate and colorectal cancers26–36. In addition, amounts in expression of its 
receptor (VDR), expression of hydroxylases participating in its activation and metabolism (CYP27B1, CYP24A1), 
as well as the expression of the alternative receptors, retinoic acid-related orphan receptors α and γ (RORα and 
RORγ) in tumor tissues can affect the outcome of the disease26–29,31–37.
Because of such versatile actions of vitamin D, more and more scientists have taken up the research concern-
ing its function in ophthalmologic diseases. Decreased levels of vitamin D metabolites in blood serum have been 
linked to an increased risk of age-related macular degeneration (AMD), dry eye syndrome, diabetic retinopathy 
and impaired corneal healing after surgeries and traumas38–42.
The studies carried out by Alsalem et al. confirmed the presence of VDR and CYP27A1, CYP2R1, CYP27B1, 
CYP24A1 in the cells of the protective barrier of human eye, i.e. primary human scleral fibroblasts (HSF), in cul-
tured corneal endothelial cells (HCEC-12), adult retinal pigment epithelial (ARPE-19), and nonpigmented ciliary 
body epithelial cells (ODM-2)43.
Other receptors linked to the control of cellular functions by sterols44–46, including vitamin D47,48 and 
lumisterol compounds49, are the nuclear receptors RORα and RORγ. These transcription factors regulate several 
physiological and pathological processes, including various immune and endocrine functions, as well as cell 
growth, differentiation, apoptosis, and cancer50–56. RORα and RORγ also participate in the regulation of circadian 
rhythms by directly regulating the expression of a number of clock genes57,58.
New vitamin D hydroxyderivatives that can also act as inverse agonists on ROR are produced ex-vivo by adre-
nal and placenta fragments, epidermal keratinocytes and are detectable in human epidermis and serum59–61. It 
has been recently demonstrated that RORα and RORγ are expressed in normal and pathological human skin and 
that hydroxyderivatives of vitamin D can act as inverse agonists of ROR47,49,54. In cutaneous melanoma a inverse 
correlation between the RORα and RORγ expression and the progression of human cutaneous melanoma has 
been observed62.
To fill the gap in our knowledge on vitamin D activity in uveal melanoma, we decided to evaluate the expression 
pattern of the VDR, CYP27B1 and CYP24A1 hydroxylases and RORα and RORγ in the cells of uveal melanoma, 
in normal melanocytes and in other normal uveal cells in humans. Additionally, the relationship between VDR, 
CYP27B1, CYP24A1, RORα and RORγ expression, with clinical presentation and melanin content were examined.
Results
Expression of the VDR in human uveal tract and uveal melanoma. Similarly as in the cells of cuta-
neous melanoma, VDR immunostaining has been found in uveal melanoma both in cell nuclei (VDRn) and in 
cytoplasm (VDRc). The presence of nuclear vitamin D receptor (VDRn) was observed in all types of the uveal 
tissues of adult patients. VDRn was present both in the tumor cells (uveal melanoma, 100%), and in non-tumor 
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cells, such as normal melanocytes (uveal melanocytes, 96.77%) and other normal cells of the surrounding con-
nective tissue (fibroblasts, 70.97%) (Fig. 1A–E). The difference in the number of evaluated receptors between 
normal and tumor tissue was statistically significant. In the tumor cells, the level of VDRn was significantly lower 
(the Wilcoxon signed-rank test, p < 0.001). The analysis showed also a statistically significant difference between 
the numbers of VDRn in normal cells of the uveal tissue. Melanocytes contained less VDRn than other cells of 
connective tissue did (the Wilcoxon signed-rank test, p = 0.002) (Fig. 1F). In uveal melanoma, the presence of 
cytoplasmic vitamin D receptors (VDRc) was found (Me = 25.0, and Q1 = 10, Q3 = 43.75).
CYP24A1 and CYP27B1 in human uveal tract and uveal melanoma. CYP24A1, a mitochondrial 
monooxygenase belonging to the cytochrome P450 – superfamily, was found to be expressed in melanoma cells 
(90.32%), normal uveal melanocytes (67.74%) and other normal cells (54.84%) of the choroid coat (Fig. 2A–E). 
Mitochondrial monooxygenase is an enzyme, whose core function is the hydroxylation of an active form of 
1.25-dihydroxyvitamin D3 into its inactive one. The lowest average values of this enzyme were found in the mela-
noma cells, larger ones – in normal melanocytes, whilst the largest – in other normal uveal cells.
The Wilcoxon signed-rank test showed that the immunostaining CYP24A1 distribution in uveal melanoma 
and uveal melanocytes, uveal melanoma and other uveal cells significantly differ from each other (p < 0.001) 
(Fig. 2F).
The presence of another enzyme belonging to cytochrome P450 superfamily, CYP27B1, and also known 
as 1-alpha-hydroxylase was found in 96.77% melanoma, 100% melanocytes, and in 70.97% other normal cells 
of the choroid coat (Fig. 3A–E). This enzyme catalyzes calcidiol (25(OH)D3) hydroxylation to calcitriol, i.e. 
1,25(OH)2D3, the bioactive form of vitamin D.
In uveal melanoma, the values of CYP27B1 labelling were significantly lower than in normal melanocytes and 
other uveal cells (the Wilcoxon signed-rank test, p < 0.001) (Fig. 3F).
RoRα and RoRγ in human uveal tract and uveal melanoma. Similarly, to cutaneous melanoma 
cells, RORα and RORγ were found to be expressed in both the nuclei (RORαn, RORγn), and the cytoplasm 
(RORαc, RORγc) of uveal melanoma and normal tissue. RORα and γ (NR1F1 and NR1F3, respectively) are 
member of the nuclear receptor superfamily47 that regulate gene transcription in many cell types. In our study, 
we observed expression of RORα in the nuclei (RORαn) of melanoma cells (93.55%), normal uveal melanocytes, 
(54.84%) and other normal uveal cells (64.52%) (Fig. 4A–E). The values of immunostaining of RORαn differed 
Figure 1. Representative VDR immunostaining in uveal pigmented cells (A), other cells (B), strongly 
pigmented (C) and slightly pigmented (D) melanomas and negative (E; two separate samples separated with 
dotted line) and positive (F) controls. Inserts present high magnification of negative (VDR−) and positive 
(VDR+) cell nuclei (as indicated by arrow heads). Arrows indicate nuclear VDR immunostaining, asterisks 
indicate melanin, scale bar: 50 μm. Mean nuclear VDR immunolabelling (A.U. – arbitrary units) in melanoma, 
normal melanocytes and other normal uveal cells (F) (statistically significant differences are denoted with the 
Wilcoxon signed-rank test).
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significantly between the tumor cells of the uveal melanoma, normal melanocytes and other uveal cells (the 
Wilcoxon signed-rank test, p < 0.001). Concerning differences between normal melanocytes and other normal 
uveal cells, there were no differences in immunostaining (the Wilcoxon signed-rank test, p = 0.557) (Fig. 4F). 
RORα immunostaining of the cytoplasmic component in the uveal melanoma cells was found in 93.55% of cells. 
Median was 2.50, and Q1 = 0.00 and Q3 = 7.50.
RORγ expression was observed in 93.55% of melanoma cells and in normal melanocytes (93.55%), as well as 
in other normal cells (77.40%) (Fig. 5A–E). Similar to RORα, the lowest level of nuclear RORγ was observed in 
the uveal melanoma cells. Nuclear immunostaining (median value) of this receptor differed between the tumor 
cells of the uveal melanoma and normal melanocytes and other normal uveal cells (the Wilcoxon signed-rank 
test, p < 0.001), with the lack of statistical significance between normal melanocytes and other normal uveal cells 
(the Wilcoxon signed-rank test, p = 0.718) (Fig. 5F). In uveal melanoma cells, also RORγc cytoplasmic immunos-
taining (93.55%) was observed. The median was 10.00, and Q1 = 5.00 and Q3 = 17.50.
The correlation of VDR immunostaining and melanin in uveal melanoma. The analysis of VDRn, 
VDRc and all VDR (VDRa = VDRn + VDRc) immunostaining and the degree of melanin pigmentation in uveal 
melanoma cells showed a negative correlation with the levels of VDRn and VDRa to melanin (Spearman’s rank 
correlation r = −0.704, p = 0.001 and r = −0.666; p = 0.004 respectively) (Fig. 6A). No such significant correla-
tion was found for VDRc (r = −0.320, p = 0.079).
Correlation between CYP24A1 and CYP27B1 immunostaining and melanin content in uveal 
melanoma. The correlation was statistically significant only for CYP24A1 expression in comparison to the 
melanin levels in uveal melanoma (p = 0.020). With low melanin levels, the level of CYP24A1 was the lowest 
(mean level = 14.6875, SD = 7.37243), reaching the highest values at medium melanin level (mean level = 33.5417, 
SD = 719.32698), and reversed with the highest levels of melanin (mean level = 17.8333, SD = 13.73806) (Fig. 6B).
No significant correlations between CYP27B1 labelling and melanin were found. The graph shows that 
CYP27B1 level has the trend to decrease when the melanin content increases, yet this is not statistically significant 
(rho = −0.30, p = 0.111) (Fig. 6C).
Correlation between RoRα and RoRγ immunostaining and melanin content in uveal mel-
anoma. The evaluation of RORα and melanin level in uveal melanoma did not reveal any significant 
Figure 2. Representative CYP24A1 immunostaining in uveal pigmented cells (A), other cells (B), strongly 
pigmented (C) and slightly pigmented (D) melanomas and negative (E) and positive (F) controls. For CYP24A1 
in addition to normal skin (left) also kidney (right) samples served as positive controls. Arrows indicate 
CYP24A1 immunostaining, asterisks indicate melanin, scale bar: 50 μm. Mean CYP24A1 immunolabelling in 
melanoma, normal melanocytes and other normal uveal cells (F) (statistically significant differences are denoted 
with the Wilcoxon signed-rank test).
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correlations. Solely a tendency to reverse proportion (p = 0.576) was observed. For lower melanin values, the 
level of RORαn was increased.
The analysis of the correlation between RORγ immunostaining and melanin in the tumor cells showed statis-
tical correlation, indicating that RORγn was higher in the tumors with a lower (<50%) melanin level (p = 0.030) 
(Fig. 6D).
The relationship between VDRn, VDRc, VDRa and CYP24A1 and CYP27B1 in uveal mela-
noma. No significant correlations between VDR and CYP24A1 in the cells of uveal melanoma were found. 
However, there was a tendency observed, indicating that together with an increase of VDRn to the level of about 
40, the CYP24A1 value also increases (Fig. 7A).
The levels of VDRn and VDRa increased together with those of the CYP27B1 value (Spearman’s rank cor-
relation, rho = 0.401, p = 0.028 and rho = 0.390, p = 0.033, respectively) in uveal melanoma cells. For VDRc a 
tendency of reverse correlation is observed, but without a statistical significance p = 0.254 (rho = 0.22) (VDRn, 
VDR and VDRa to CYP27B1) (Fig. 7B–D).
Correlation between VDR immunolabeling and RoRα and RoRγ in uveal melanoma. The anal-
ysis of VDR and ROR immunostaining in the tumor cells revealed a statistically significant positive correlation 
between RORαn and VDRn in the melanoma cells (p = 0.030). No such correlation in the melanoma cells was 
found between RORαn and VDRc and VDRa (p = 0.476 and p = 0.118 respectively). In the melanoma cells, 
increased levels of RORγn correlated with increased levels of VDRn (p = 0.006) and VDRa (p = 0.022). No corre-
lation was found between the levels of RORα or RORγ and CYP24 or CYP27.
The relationship between VDR and clinical and pathomorphological features. Lack of statis-
tically significant correlations were found between the levels of VDR (with one exception described above), 
CYP27B1, CYP24A1 and ROR, and histopathological diagnosis of uveal melanoma (spindle-cell melanoma, 
mixed and epithelioid cell-type), the degree of sclera infiltration, the degree of optic disc infiltration, the presence 
of tumor cell emboli in the scleral vessels, the involvement of the ciliary body, tumor size (the largest base diam-
eter and height), tumor shape (mushroom-shaped, dome-shaped and diffuse), the clinical advancement stage 
(AJCC) and 2-year survival. Some tendencies could be observed, yet without statistical significance.
The only exception was the statistically significant correlation between the levels of VDRn and VDRa, and 
clinically assessed degree of tumor pigmentation (p = 0.001 and p = 0.004 respectively). In amelanotic tumors, the 
levels of VDRn were the highest, then VDRn decreased in medium-pigmented ones, whilst the lowest values were 
Figure 3. Representative CYP27B1 immunostaining in uveal pigmented cells (A), other cells (B), 
strongly pigmented (C) and slightly pigmented (D) melanomas and negative (E) and positive (F) controls. 
Arrows indicate CYP27B1 immunostaining, asterisks indicate melanin, scale bar: 50 μm. Mean CYP27B1 
immunolabelling in melanoma, normal melanocytes and other normal uveal cells (F) (statistically significant 
differences are denoted with the Wilcoxon signed-rank test).
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observed in the strongly-pigmented (dark brown) uveal melanomas (Fig. 8A). The same correlation was found for 
VDRa (Fig. 8B). No such correlation was found for VDRc (p = 0.072).
Discussion
In this study, we provide evidence for the existence of vitamin D signaling in normal uveal cells (fibroblasts and 
melanocytes) and in tumors originating from this part of the eyeball in humans, i.e. uveal melanoma. Our study 
provides evidence showing the presence of VDR and CYB27B1 and CYP24A1, hydroxylases taking part in vita-
min D metabolism, as well as RORα and RORγ, alternative receptors for vitamin D-hydroxyderivatives.
In all of the tissues examined the presence of nuclear receptors for vitamin D (VDRn), RORαn and RORγn, 
as well as CYB27B1 and CYP24A1, were confirmed. Moreover, cytoplasmic expression of VDR, RORα and 
RORγ (VDRc, RORαc and RORγc) was observed in the cells of uveal melanoma. The levels of VDR, CYP24A1, 
CYP27B1 and RORs were always the lowest in the cells of uveal melanoma and higher in normal uveal melano-
cytes and other normal uveal cells.
The remaining challenge is to establish molecular principles underlying the differences of protein expres-
sion between malignant and non-malignant samples. Since current study are focused on the paraffin embedded 
archival tissues, future studies on samples collected from the patients would clarify at which level these events are 
regulated, e.g., gene transcription, RNA processing, translation or posttranslational modifications.
With respect to other tumors, a similar decrease in the level of the above markers was observed in compari-
son to normal cells surrounding the tumor. In the case of breast cancer, Al.-Azhri et al. observed reduced VDR 
expression that was inversely correlated with the aggressive tumor characteristics, including large tumor size, 
hormonal receptor (HR) negativity, and triple-negative subtype (P < 0.05)63,64.
In ovarian cancers, normal ovarian epithelium showed the highest levels CYP27B1, opposed to a significant 
decrease of its expression in cancer tissue31. In urinary bladder cancer, the level of VDR and CYP27B1 in tumor 
tissues was significantly lower than in normal epithelium, which was observed by Jóźwicki et al.29. Bises and col-
leagues found a higher CYP27B1 expression in well-differentiated colon cancers compared with normal mucosa; 
however, in tumor areas showing a considerably poor differentiation, this expression was lost56. Also in skin mel-
anoma, a significantly decrease in the expression of VDR, CYB27B1, CYP24A1, RORα and RORγ was observed 
in comparison to normal melanocytes or perilesional keratinocytes28,62,65–67.
In the current study a reverse correlation was found between the melanin level and VDR in uveal melanoma. 
The same correlation was observed when the degree of lesion pigmentation was analyzed in the clinical picture 
in comparison with the nuclear VDR. In predominantly amelanotic tumors, the levels of VDR were the highest, 
then VDRn decreased in medium-pigmented (dark brown) uveal melanomas. Similar observations were made in 
Figure 4. Representative RORα immunostaining in uveal pigmented cells (A), other cells (B), strongly 
pigmented (C) and slightly pigmented (D) melanomas and negative (E) and positive (F) controls. Arrows 
indicate RORα immunostaining, asterisks indicate melanin, scale bar: 50 μm. Mean RORα nuclear (RORαn) 
immunolabeling in melanoma, normal melanocytes, and other normal uveal cells (F) (statistically significant 
differences are denoted with the Wilcoxon signed-rank test).
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the studies cutaneous melanoma, where the level of VDR decreased together with an increase of melanin content 
and poorer prognosis27,65. It was also shown that melanogenesis induction in human SKMel-188 melanoma cells 
was accompanied by a marked decrease in VDR expression and responsiveness to active forms of vitamin D26,68. 
Several reports have indicated that in uveal melanoma, the risk of metastases increases with increased tumor 
pigmentation7,69. In the above context, the loss of the protective function of vitamin D could be secondary to the 
reduction of the VDR expression by an increased melanogenesis. Of note, melanogenesis can affect biological 
functions of melanoma cells70–75 and normal melanocytes76,77.
Vitamin D metabolism is connected to the CYPs expression, which catalyze the reaction in which the active 
form of vitamin D is formed or metabolized to biologically inactive forms. In our study we confirmed the pres-
ence of CYP27B1 and CYP24A1 in the melanoma cells and their connection with the VDR level. Together with 
an increase of the CYP27B1 value, the levels of VDRn and VDRa were increasing and, for VDRc, a tendency of 
a direct proportionality was observed. In the case of CYP24A1, together with an increase of VDRn in the mel-
anoma to the level of about 40, the CYP24A1 value also increased. However, once this value was reached, there 
was a lack of statistical significance for any further correlation. The above results are similar to those reported for 
other tumors including cutaneous melanoma66.
Thus, the decreases in both CYP27B1 and VDR expression in uveal melanomas could reflect defects in the 
local vitamin D signaling pattern, which could facilitate melanoma progression and invasion. Similar findings 
were made by Brożyna et al. in a study on cutaneous melanomas67. Patients with low CYP27B1 and VDR expres-
sion had a shorter overall survival. Moreover, an absence of CYP27B1 or a reduction promoted the development 
of metastases and correlated with shorter disease-free survival28,65,67. A correlation was found between the level 
of CYP24A1 and melanin in uveal melanoma, yet no correlations were observed between the CYP27B1 labelling 
and melanin.
With respect to ROR expression in uveal melanomas, it was found that together with an increase of RORαn, 
the level VDRn increased significantly and, together with an increase of RORγn in melanoma, the levels of 
VDRn and VDRa (p = 0.022) also increased. No significant correlations between RORαn and VDRc or VDR 
and between RORγn and VDRc were found, yet some tendency of direct proportional correlation was observed 
in these cases.
Our analysis on the correlation between RORα and RORγ and the presence of melanin in uveal melanoma, 
showed only a tendency for reverse correlation for RORα. Thus, lower levels of melanin was associated with 
increased expression of RORαn. Likewise, RORγn was higher in the tumors with a lower level of melanin. These 
observation are in agreement with observations made in cutaneous melanomas the expression level of RORα and 
RORγ decreased in strongly pigmented melanomas62.
Figure 5. Representative RORγ immunostaining in uveal pigmented cells (A), other cells (B), strongly 
pigmented (C) and slightly pigmented (D) melanomas and negative (E) and positive (F) controls. Arrows 
indicate RORγ immunostaining, asterisks indicate melanin, scale bar: 50 μm. Mean RORγ nuclear (RORγn) 
immunolabelling in uveal melanoma, normal melanocytes and other normal uveal cells (F) (statistically 
significant differences are denoted with the Wilcoxon signed-rank test).
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Vitamin D has the number of confirmed anti-tumor functions, acting through VDR, such as inhibition of cell 
proliferation, accelerated apoptosis, regulation of the cell cycle and differentiation, among others thanks to the 
presence of FOXO protein, cyclin-dependent kinase inhibitors like p21 or p27, insulin-like growth factor (IGF), 
transforming growth factor beta (TGFβ), and Wnt-β/catenin24. These also include anti-tumor effects in cutaneous 
melanomas26,27. Therefore, we propose that higher levels of VDR in uveal melanoma might be connected with a 
better prognosis in this disease. Taking into consideration that metastases of uveal melanoma, as opposed to cuta-
neous melanoma, can occur after many years, further observation of the reported patients during the follow-up 
period is required for definitive conclusions. The confirmation of the above pattern on a larger group of patients 
with simultaneous correlation with the clinical outcome are required to better define the VDR as a prognostic 
factor. This would open the way for creating new adjuvant therapies of uveal melanoma that would base on vita-
min D derivatives, as it has been demonstrated for other tumors including cutaneous melanoma. Additional open 
questions are whether the levels of VDR, CYP27B1 and CYP24A1 and ROR in the tumor cells can also serve as 
reliable prognostic factors and in what way the level of VDR may affect the efficiency of vitamin D in inhibiting 
the tumor growth and aggressiveness.
In conclusion, we provide an evidence for the presence of the VDR, CYB27B1, CYP24A1, RORα and RORγ 
in uveal cells, which changes in uveal melanomas and suggest that these proteins are involved in clinical presenta-
tion and represent targets for novel therapeutic approaches.
Materials and Methods
The study involved 31 adult patients in whom, on account of uveal melanoma, the eyeballs were enucleated 
during the period between 2013 and 2014 in the Department of Ophthalmology and Ocular Oncology, Medical 
College of Jagiellonian University in Kraków, Poland. For all patients, enucleation was the only way to treat the 
affected eye, with no previous local or systemic therapies. The study group comprised 19 women (61.30%) and 12 
(38.70%) man, at the age ranging from 39 and 83 years (mean age: 62.9, SD = 10.8). The tissues of the enucleated 
eyeball were examined, with special attention paid to the medium layer, i.e. the choroid coat and to the primary 
tumor – melanoma originating from pigment cells (melanocytes) of this part of the eye. The disease affected 
the left eye more frequently (22 cases; 71.00%) than the right one (9 cases; 29.00%). The clinical TNM stage of 
the cancer was T3 in 17 cases (54.80%) cases and T4 in 14 cases (45.20%), whilst the AJCC stage was in 4 cases 
(12.90%) IIa, and in 13 cases – (41.90%) IIb, in 7 cases (22.60%) – IIIa, in 4 cases (12.90%) IIIb and in 3 cases 
(9,70%) IIIc78.
Figure 6. The correlation of: VDRn immunostaining and the level of melanin (A); CYP24A1 immunostaining 
and melanin (B); CYP27B1immunostaining and melanin (C); RORγn immunostaining and melanin (D).
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In the ultrasound picture, a mushroom-shaped tumor was dominating (19; 61.30%), followed by dome-shaped 
one (11; 35.50%), and only in 1 case (3.20%) a diffuse shape was observed. In all cases, histopathological assess-
ment confirmed the diagnosis of uveal melanoma. In 25 cases (80.60%) it was melanoma of the choroid coat, in 
4 cases (12.90%) of the choroid coat and ciliary body, and in 2 cases (6.50%) of the choroid coat, ciliary body and 
iris. On the basis of the modified Callender’s classification of uveal melanoma, the following histopathological 
subtypes of melanoma were diagnosed: spindle-cell – in 11 cases (35.50%), mixed – in 13 cases (41.90%) and 
epithelioid cell-type in 7 cases (22.60%). The eyeball infiltration and extra-bulbar infiltration were observed in 
6 cases (19.40%) and in 5 cases (16.10%) cases respectively. Necrosis was found in 3 (9.75%) tumors. Optic disc 
involvement was observed in 11 cases (35.50%), and the involvement of ciliary body in 6 (19.40%) tumors.
The degree of tumor pigmentation (light, i.e. predominantly-amelanotic, medium-pigmented and 
strongly-pigmented, i.e. dark-brown) was assessed by 2 ophthalmologists working independently, during the enu-
cleation procedure (after the resection, in order to collect the study specimen) and/or during an ophthalmoscopic 
Figure 7. The correlation between VDRn immunostaining and CYP24A1 level (A). The correlation of the level 
of CYP27B1 to VDRn (B), VDRc (C) and VDRa (D).
Figure 8. Comparison of VDRn (A) and VDRa (B) expression with the clinical assessment of tumor 
pigmentation (the Wilcoxon signed-rank test).
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assessment or on the basis of the evaluation of the photograph of the patient eye fundus. Additionally, for 
the purpose of further analysis, the percentage content of melanin in all the histopathological specimens was 
made, distinguishing 3 groups depending on the melanin level: 0–10 (predominantly-amelanotic), 11–50 
(medium-pigmented) and 51–100 (with strong pigmentation). In all the cases, the clinical assessment and his-
topathological assessment overlapped. In the analyzed tumors, 8 predominantly-amelanotic types (25.80%), 13 
medium-pigmented types (41.90%) and 10 types with strong pigmentation (32.30%) were found.
The follow-up period was 2 years. The analysis of the overall survival (OS) in this period found that 8 patients 
(25.80%) died during that period, out of whom 6 patients (19.40%) died of the dissemination of uveal melanoma, 
1 person (3.20%) died of a different cancer and another 1 person (3.20%) died of a sudden cardiac arrest. In the 
evaluation of the disease free survival (DFS) in that period, no case of local recurrence in the orbit was found, 
but in 8 patients (25.80%), cancer dissemination was found on additional assessments. In all these cases, some 
numerous isolated metastases in the liver were found and, additionally, in 1 case (3.20%) melanoma foci were 
observed in the lungs.
In all the specimens, the tissue of uveal melanoma, normal melanocytes and connected tissue cells of the 
choroid coat were analyzed with regards to the presence of nuclear and cytoplasmic vitamin D receptors for and 
enzymes taking part in its metabolism, such as CYP27B1 and CYP24A1, in the manner described below. In these 
cells also the presence of RORα and RORγ was assessed.
After the presence of all the above markers was found, their qualitative and quantitative analyses were made 
and then, with the use of statistical analysis tools, the correlations between these markers and also between these 
markers and the clinical features (including pathomorphological ones) of uveal melanoma were evaluated.
Authors declare that this investigation was carried out following the rules of the Declaration of Helsinki 
of 1975 (revised in 2008) and this study was approved by the Ethics Committee of the Jagiellonian University, 
Krakow, Poland (No 1072.6120.34.2017, 20 June 2017). The Bioethical Committee of the Jagiellonian University 
(Poland), which gave their permission for conducting this study, waived the requirement to obtain Patients’ 
informed consent for this research.
VDR, CYP27B1, CYP24A1, RORα and RoRγ immunohistochemistry. VDR, CYP27B1, CYP24A1, 
RORα and RORγ expression was detected using immunohistochemistry as previously described28,29,31,61,65,66,79 
with slight modifications. Briefly, formalin-fixed, paraffin-embedded 4µm-sections, after antigen retrieval in high 
pH buffer using PT-Link device (Dako, Glostrup, Denmark), were stained overnight using appropriate antibodies 
(Table 1). Imm-PACT NovaRED (Vector Laboratories Inc., Burlingame, CA, USA) was used as a substrate for 
peroxidase for visualization. Then, sections were counterstained with hematoxylin (except VDR immunostain-
ing), and mounted under the non-aqueous medium (Consul Mount; Thermo Fisher Scientific Inc. Waltham, MA, 
USA). For negative controls primary antibodies were replaced with antibody diluent. Samples of normal skin 
served as positive control. In addition, for CYP24A1 kidney samples were used as additional positive controls.
Evaluation of immunostained sections has been performed by two independent observers in a blind man-
ner, without knowing the detailed histopathological diagnosis and the clinical data. VDR, CYP27B1, CYP24A1, 
RORα and RORγ immunostaining of melanomas was scored semiquantitatively as previously described and 
both staining intensity, using a four-point scale, and percentage of cells was evaluated and calculated as fol-
lows: SQ = mean(IR × SI)/100, where IR is the percentage of immunoreactive cells and SI is the staining intensity 
(assessed using the scale from 0 to 3 arbitrary units (A.U.). The staining intensity in positive controls served as 
reference for staining intensity evaluation in samples of uveal melanoma samples. Since the immunostaining 
of CYP24A1 in normal skin samples were heterogenous between different samples, CYP24A1 were assessed in 
relation to its expression in the kidney28,29,31,61,65,66,79.
Antibody Vendor
Permeabilization/blocking 





Secondary antibody (dilution; incubation 
time; vendor)
Anti-VDR, rat monoclonal, 
clone 9A7
Abcam (Abcam Inc., 
Cambridge, MA, USA) NA 1:50, O/N, 4 °C
anti-rat, peroxidase-conjugated goat antibody 
(1:250, 30 min, Jackson ImmunoResearch 
Laboratories, Inc. West Grove, PA, USA);
Anti-CYP27B1, rabbit 
polyclonal, clone H-90
Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA, USA) 0.2% Triton-X100, 15 min, RT 1:75, O/N, 4 °C
EnVision System-HRP (RTU, 30 min, 
antibody with peroxidase-conjugated polymer 
backbone,Dako, Carpinteria, CA, USA)
Anti-CYP24A1, mouse 
monoclonal,
Abcam (Abcam Inc., 
Cambridge, MA, USA)
0.2% Triton-X100 in 1% BSA, 
25 min, RT 1:30, O/N, 4 °C
EnVision System-HRP (RTU, 30 min, antibody 
with peroxidase-conjugated polymer backbone, 
Dako, Carpinteria, CA, USA)
Anti-RORα, goat 
polyclonal, clone C-16
Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA, USA) 2% BSA, 20 min, RT 1:500, O/N, 4 °C
EnVision System-HRP (RTU, 30 min, 
antibody with peroxidase-conjugated polymer 
backbone,Dako, Carpinteria, CA, USA)
Anti-RORγ, rabbit customer-made at NIEHS by Dr Jetten*
0.1% Triton-X100 in 3.5% 
BSA, 60 min, RT 1:50, O/N, 4 °C
EnVision System-HRP (RTU, 30 min, 
antibody with peroxidase-conjugated polymer 
backbone,Dako, Carpinteria, CA, USA)
Table 1. Description of the antibodies used and their manufacturers, and of immunocytochemistry protocols 
and detection methods. RT – room temperature, O/N, overnight; NA – not applied; BSA- bovine serum 
albumin; RTU – ready-to-use; *for detailed description see47,62. The melanin content was assessed in routine 
pathomorphological slides (stained with hematoxylin and eosin) as previously described62,79.
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Statistical analysis. The distribution of qualitative variables was described with the absolute numbers in 
specific categories (n) and their percentage distribution in that variable (%). Average values of variables with 
normal distribution were described with the mean value and standard deviation (SD), whilst in the case of vari-
ables whose distributions were significantly different from the normal ones – with the median and quartiles: the 
first and the third ones. The compliance of the distribution of a given variable with the normal distribution was 
assessed with the Shapiro-Wilk test, and with skewness and also it was visually evaluated by means of histogram 
analysis, boxplot and Q-Q plot (quantile-quantile).
Distributions of the studied variables were presented using boxplots, where bolded line at the interior of the 
box represents median, lower and upper end of the box (hinges) represent the 1st and the 3rd quartile, respectively. 
Whiskers represent observations ranging up to 1.5 of interquartile range from the box, circles represent obser-
vations ranging from 1.5 up to 3 interquartile ranges above or below from the hinges, and asterisks represent 
observations lying above or below 3 interquartile ranges from the hinges.
Relationships between particular variables were presented as scatterplots with added locally smoothed lowest 
curve, estimated using Epanechnikov algorithm.
The comparison of mean values of the variables with normal distribution in two nonrelated groups was made 
with the t-Student test for independent groups, whilst in more than two unrelated groups – with the ANOVA 
analysis of variance. The comparison of mean values of variables with distribution different significantly from 
normal ones in two unrelated groups was made with the Mann-Whitney test, whilst in more than two unrelated 
groups with the Kruskal-Wallis test. The comparison of mean values of the variables with the distributions differ-
ent significantly from normal ones in two unrelated groups was made with the Wilcoxon test for related variables 
measured on interval or ordinal scale.
The strength of the correlation between the variables measured in interval scale was evaluated with the 
Pearson correlation coefficient, when between the variables there was a straight-line relationship, whilst, with 
Spearman’s Rho coefficient when the relationship was monotonous, but not a straight-line one, and in all other 
cases – with the eta correlation coefficient. A graphic presentation of the correlations between the analyzed vari-
ables was made with a scatterplot with the plugged loess curve, illustrating mean values of the variable presented 
on the Y axis and corresponding to the values of the variable presented in the X axis. The effects with the value 
p < 0.05 were regarded as statistically significant. The calculations were made with the IBM SPSS Statistics 24 for 
Windows software.
References
 1. Chang, A. E., Karnell, L. H. & Menck, H. R. The National Cancer Data Base Report on Cutaneous and Noncutaneous Melanoma. 
Cancer 83, 1664–1678, https://doi.org/10.1002/(SICI)1097-0142(19981015)83:83.0.CO;2-G (1998).
 2. Shields, C. L. et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch. Ophthalmol 127, 
989–998, https://doi.org/10.1001/archophthalmol.2009.208 (2009).
 3. Kaliki, S. & Shields, C. L. Uveal melanoma: Relatively rare but deadly cancer. Eye 31, 241–257 (2017).
 4. Singh, A. D., Turell, M. E. & Topham, A. K. Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology 118, 
1881–1885, https://doi.org/10.1016/j.ophtha.2011.01.040 (2011).
 5. Virgili, G. et al. Incidence of Uveal Melanoma in Europe. Ophthalmology 114, https://doi.org/10.1016/j.ophtha.2007.01.032 (2007).
 6. Kivelä, T. The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. Br J 
Ophthalmol 93, 1129–1131, https://doi.org/10.1136/bjo.2008.150292 (2009).
 7. Shields, C. L. et al. Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture. Eye 29, 1027–1035, https://
doi.org/10.1038/eye.2015.51 (2015).
 8. Al-Jamal, R. T. et al. The pediatric choroidal and ciliary body melanoma study: A survey by the European Ophthalmic Oncology 
Group. Ophthalmology 123, 898–907, https://doi.org/10.1016/j.ophtha.2015.12.024 (2016).
 9. Echegaray, J. J., Bechrakis, N. E., Singh, N., Bellerive, C. & Singh, A. D. Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic 
Review of Radiation Dose. Ocul. Oncol. Pathol 3, 193–198, https://doi.org/10.1159/000455872 (2017).
 10. Verma, V. & Mehta, M. P. Clinical Outcomes of Proton Radiotherapy for Uveal Melanoma. Clin Oncol 28, 17–27, https://doi.
org/10.1016/j.clon.2016.01.034 (2016).
 11. Diener-West, M. et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: 
Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 123, 1639–1643, https://doi.org/10.1001/
archopht.123.12.1639 (2005).
 12. Postow, M. A., Kuk, D., Bogatch, K. & Carvajal, R. D. Assessment of overall survival from time of metastastasis in mucosal, uveal, 
and cutaneous melanoma. J Clin Oncol 32, 9074, https://doi.org/10.1200/jco.2014.32.15_suppl.9074 (2014).
 13. Kujala, E., Mäkitie, T. & Kivelä, T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 
44, 4651–4659, https://doi.org/10.1167/iovs.03-0538 (2003).
 14. Zhu, J. & DeLuca, H. F. Vitamin D 25-hydroxylase - Four decades of searching, are we there yet? Arch Biochem Biophys 523, 30–36, 
https://doi.org/10.1016/j.abb.2012.01.013 (2012).
 15. Jones, G., Prosser, D. & Kaufmann, M. Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res 55, 13–31, https://doi.
org/10.1194/jlr.R031534 (2014).
 16. Christiakos, S., Dhawan, P., Verstuyf, A., Verlinden, L. & Carmeliet, G. Vitamin D: Metabolism, Molecular Mechanism of Action, 
and Pleiotropic Effects. Physiol Rev 96, 365–408, https://doi.org/10.1152/physrev.00014.2015 (2016).
 17. Bikle, D. D. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 21, 319–29, https://doi.org/10.1016/j.
chembiol.2013.12.016 (2014).
 18. Wacker, M. & Holic, M. F. Sunlight and Vitamin D: A global perspective for health. Dermatoendocrinol 5, 51–108, https://doi.
org/10.4161/derm.24494 (2013).
 19. Bikle, D. D. Vitamin D: an ancient hormone. Exp Dermatol 1, 7–13 (2011).
 20. Hossein-Nezhad, A. & Holick, M. F. Vitamin D for health: A global perspective. Mayo Clinic Proceedings 88, 720–755, https://doi.
org/10.1016/j.mayocp.2013.05.011 (2013).
 21. Prietl, B., Treiber, G., Pieber, T. R. & Amrein, K. Vitamin D and immune function. Nutrients 5, 2502–2521, https://doi.org/10.3390/
nu5072502 (2013).
 22. Holick, M. F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. 
Am J Clin Nutr 80, 678S–1688S, https://doi.org/10.1093/ajcn/80.6.1678S (2004).
 23. Caccamo, D., Ricca, S., Currò, M. & Ientile, R. Health risks of hypovitaminosis D: A review of new molecular insights. Int J Mol Sci, 
19, https://doi.org/10.3390/ijms19030892 (2018).
1 2Scientific RepoRts |          (2019) 9:9142  | https://doi.org/10.1038/s41598-019-45161-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
 24. Fleet, J. C., Desmet, M., Johnson, R. & Li, Y. Vitamin D and Cancer: A review of molecular mechanisms. Biochem J 441, 61–76, 
https://doi.org/10.1042/BJ20110744 (2012).
 25. Feldman, D., Krishnan, A. V., Swami, S., Giovannucci, E. & Feldman, B. J. The role of vitamin D in reducing cancer risk and 
progression. Nat Rev Cancer 14, 342–357, https://doi.org/10.1038/nrc3691 (2014).
 26. Slominski, A. T. et al. On the role of classical and novel forms of vitamin D in melanoma progression and management. J Steroid 
Biochem Mol Biol 177, 159–170, https://doi.org/10.1016/j.jsbmb.2017.06.013 (2018).
 27. Slominski, A. T. et al. Vitamin D signaling and melanoma: Role of Vitamin D and its receptors in melanoma progression and 
management. Lab Investig 97, 706–724, https://doi.org/10.1038/labinvest.2017.3 (2017).
 28. Brozyna, A. A., Jozwicki, W., Slominski, A. T. & Decreased, V. D. R. expression in cutaneous melanomas as marker of tumor 
progression: New data and analyses. Anticancer Res 34, 2735–2744 (2014).
 29. Jozwicki, W., Brozyna, A., Siekiera, J. & Slominski, A. Expression of Vitamin D Receptor (VDR) Positively Correlates with Survival 
of Urothelial Bladder Cancer Patients. Int J Mol Sci 16, 24369–24386, https://doi.org/10.3390/ijms161024369 (2017).
 30. Edrei, R. & Kimel, S. Oxygen depletion during in vitro photodynamic therapy: structure-activity relationships of sulfonated 
aluminum phthalocyanines. J Photochem Photobiol 50, 197–203 (1999).
 31. Brozyna, A. A., Jozwicki, W., Jochymski, C. & Slominski, A. T. Decreased expression of CYP27B1 correlates with the increased 
aggressiveness of ovarian carcinomas. Oncol Rep 33, 559–606, https://doi.org/10.3892/or.2014.3666 (2015).
 32. Hu, M. et al. Association between vitamin D deficiency and risk of thyroid cancer: a case–control study and a meta-analysis. J 
Endocrinol Invest, https://doi.org/10.1007/s40618-018-0853-9 (2018).
 33. Pereira, F., Larriba, M. J. & Muñoz, A. Vitamin D and colon cancer. Endocr Relat Cancer 19, R51–71, https://doi.org/10.1530/ERC-
11-0388 (2012).
 34. Zhang, L., Wang, S., Che, X. & Li, X. Vitamin D and lung cancer risk: A comprehensive review and meta-analysis. Cell Physiol 
Biochem 36, 299–305, https://doi.org/10.1159/000374072 (2015).
 35. Der, T. et al. Vitamin D and Prostate Cancer Survival in Veterans. Mil Med 179, 81–84, https://doi.org/10.7205/
MILMED-D-12-00540 (2014).
 36. Barreto, S. G. & Neale, R. E. Vitamin D and pancreatic cancer. Cancer Lett 368, 1–6, https://doi.org/10.1016/j.canlet.2015.06.030 
(2015).
 37. Kim, Y. & Je, Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: A meta-analysis. Br J Cancer 110, 
2772–2784, https://doi.org/10.1038/bjc.2014.175 (2014).
 38. Jee, D. et al. Serum 25-hydroxyVitamin D levels and dry eye syndrome: Differential effects of Vitamin D on ocular diseases. PLoS 
One 11, https://doi.org/10.1371/journal.pone.0149294 (2016).
 39. Reins, R. Y. & McDermott, A. M. Vitamin D: Implications for ocular disease and therapeutic potential. Exp Eye Res 134, 101–110, 
https://doi.org/10.1016/j.exer.2015.02.019 (2015).
 40. Meng, Y. F., Lu, J., Xing, Q., Tao, J. J. & Xiao, P. Lower Serum Vitamin D Level Was Associated with Risk of Dry Eye Syndrome. Med 
Sci Monit 23, 2211–2216, https://doi.org/10.12659/msm.901857 (2017).
 41. Reins, R.Y., Hanlon, S. D., Magadi, S. & McDermott, A. M. Effects of topically applied Vitamin D during corneal wound healing. 
PLoS One 11, https://doi.org/10.1371/journal.pone.0152889 (2016).
 42. Layana, A. et al. Vitamin D and Age-Related Macular Degeneration. Nutrients 9, 1120, https://doi.org/10.3390/nu9101120 (2017).
 43. Alsalem, J. A. et al. Characterization of vitamin D production by human ocular barrier cells. Investig Ophthalmol Vis Sci 55, 
2140–2147, https://doi.org/10.1167/iovs.13-13019 (2014).
 44. Solt, L. A. & Burris, T. P. Action of RORs and their ligands in (patho)physiology. Trends Endocrinol Metab 23, 619–627 (2012).
 45. Kallen, J., Schlaeppi, J. M., Bitsch, F., Delhon, I. & Fournier, B. Crystal structure of the human RORalpha Ligand binding domain in 
complex with cholesterol sulfate at 2.2 A. J Biol Chem 279, 14033–8, https://doi.org/10.1074/jbc.M400302200 (2004).
 46. Kallen, J. A. et al. X-ray structure of the hRORα LBD at 1.63 Å: Structural and functional data that cholesterol or a cholesterol 
derivative is the natural ligand of RORα. Structure 10, 1697–1707, https://doi.org/10.1016/S0969-2126(02)00912-7 (2002).
 47. Slominski, A. T. et al. RORα and RORγ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 
20-hydroxy- and 20,23-dihydroxyvitamin D. FASEB J 28, 2775–2789, https://doi.org/10.1096/fj.13-242040 (2014).
 48. Slominski, A. T. et al. Endogenously produced nonclassical vitamin D hydroxy-metabolites act as “biased” agonists on VDR and 
inverse agonists on RORα and RORγ. J Steroid Biochem Mol Biol 173, 42–56, https://doi.org/10.1016/j.jsbmb.2016.09.024 (2017).
 49. Slominski, A. T. et al. Characterization of a new pathway that activates lumisterol invivo to biologically active hydroxylumisterols. 
Sci Rep 7, https://doi.org/10.1038/s41598-017-10202-7 (2017).
 50. Jetten, A. M. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular 
metabolism. Nucl Recept Signal 4, https://doi.org/10.1621/nrs.07003 (2007).
 51. Jetten, A. M. & Jetten, M. E. R. Possible role of retinoic acid binding protein in retinoid stimulation of embryonal carcinoma cell 
differentiation. Nature 278, 180–2, https://doi.org/10.1038/278180a0 (1979).
 52. Jetten, A. M. & Joo, J. H. Retinoid-related orphan receptors (RORs): Roles in cellular differentiation and development. Adv Dev Biol 
16, 313–355, https://doi.org/10.1016/S1574-3349(06)16010-X (2006).
 53. Jetten, A. M. & Euda, E. Retinoid-related orphan receptors (RORs): Roles in cell survival, differentation and disease. Cell Death 
Differ 9, 1167–1171, https://doi.org/10.1038/sj.cdd.4401085 (2002).
 54. Jetten, A. M., Takeda, Y., Slominski, A. & Kang, H. S. Retinoic acid-related orphan receptor γ (RORγ): Connecting sterol metabolism 
to regulation of the immune system and autoimmune disease. Curr Opin Toxicol 8, 66–80, https://doi.org/10.1016/j.
cotox.2018.01.005 (2018).
 55. Sun, Z. et al. Requirement for RORγ in thymocyte survival and lymphoid organ development. Science 288, 2369–2373, https://doi.
org/10.1126/science.288.5475.2369 (2000).
 56. Kurebayashi, S. et al. Retinoid-related orphan receptor γ (RORγ) is essential for lymphoid organogenesis and controls apoptosis 
during thymopoiesis. Proc Natl Acad Sci USA 97, 10132–10137 (2000).
 57. Liu, A. C. et al. Redundant function of REV-ERBα and β and non-essential role for Bmal1 cycling in transcriptional regulation of 
intracellular circadian rhythms. PLoS Genet 4, https://doi.org/10.1371/journal.pgen.1000023 (2008).
 58. Takeda, Y., Birault, V. & Jetten, A. M. The Retinoic acid-related Orphan Receptor γ (RORγ) directly regulates the circadian 
expression of clock genes and downstream targets in vivo. Nucleic Acids Res 40, 8519–8535 (2012).
 59. Slominski, A. T. et al. In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by 
CYP27B1. FASEB J 26, 3901–3915, https://doi.org/10.1096/fj.12-208975 (2012).
 60. Slominski, A. T. et al. Detection of novel CYP11A1-derived secosteroids in the human epidermis and serum and pig adrenal gland. 
Sci Rep 5, 14875, https://doi.org/10.1038/srep14875 (2015).
 61. Slominski, A. T. et al. In vivo production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, 
Caco-2 colon cells and the adrenal gland. Mol Cell Endocrinol 383, 181–192, https://doi.org/10.1016/j.mce.2013.12.012 (2014).
 62. Brozyna, A. A., Jozwicki, W., Skobowiat, C., Jetten, A. & Slominski, A. T. RORα and RORγ expression inversely correlates with 
human melanoma progression. Oncotarget https://doi.org/10.18632/oncotarget.11211 (2016).
 63. Al-Azhri, J. et al. Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis. Clin 
Cancer Res 344, 1173–1178, https://doi.org/10.1126/science.1249098 (2015).
 64. Bises, G. et al. 25-Hydroxyvitamin D3-1α-hydroxylase Expression in Normal and Malignant Human Colon. J Histochem Cytochem 
52, 985–989, https://doi.org/10.1369/jhc.4B6271.2004 (2004).
13Scientific RepoRts |          (2019) 9:9142  | https://doi.org/10.1038/s41598-019-45161-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
 65. Brozyna, A. A., Jozwicki, W., Janjetovic, Z. & Slominski, A. T. Expression of vitamin D receptor decreases during progression of 
pigmented skin lesions. Hum Pathol 42, 618–631, https://doi.org/10.1016/j.humpath.2010.09.014 (2001).
 66. Brozyna, A. A. et al. CYP24A1 expression inversely correlates with melanoma progression: Clinic-pathological studies. Int J Mol Sci 
15, 19000–19017, https://doi.org/10.3390/ijms151019000 (2014).
 67. Brozyna, A. A., Jozwicki, W., Janjetovic, Z. & Slominski, A. T. Expression of the vitamin D-activating enzyme 1α-hydroxylase 
(CYP27B1) decreases during melanoma progression. Hum Pathol 44, 374–387, https://doi.org/10.1016/j.humpath.2012.03.031 
(2013).
 68. Janjetovic, Z. et al. High basal NF-kB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin 
D3 derivatives. Br J Cancer 105, 1874–1884, https://doi.org/10.1038/bjc.2011.458 (2011).
 69. Kivela, T. Uveal malignant melanoma: histopathologic features. In: Singh A. D., Damato B. E., Pe’er J., Murphree A. L., Perry J. D., 
editors. Clinical Ophthalmic Oncology. Saunders-Elsevier: Philadelphia, USA, pp. 219–225 (2007).
 70. Slominski, A. et al. The role of melanogenesis in regulation of melanoma behavior: Melanogenesis leads to stimulation of HIF-1α 
expression and HIF-dependent attendant pathways. Arch Biochem Biophys 563, 79–93, https://doi.org/10.1016/j.abb.2014.06.030 
(2014).
 71. Slominski, A. T. & Carlson, J. A. Melanoma resistance: A bright future for academicians and a challenge for patient advocates. Mayo 
Clin Proc 89, 429–433, https://doi.org/10.1016/j.mayocp.2014.02.009 (2014).
 72. Slominski, R. M., Zmijewski, M. A. & Slominski, A. T. The role of melanin pigment in melanoma. Exp Dermatol 24, 258–259, https://
doi.org/10.1111/exd.12618 (2015).
 73. Sniegocka, M. et al. Transplantable melanomas in hamsters and gerbils as models for human melanoma. Sensitization in melanoma 
radiotherapy - From animal models to clinical trials. Int J Mol Sci 19, 1048, https://doi.org/10.3390/ijms19041048 (2018).
 74. Slominski, A., Paus, R. & Mihm, M. Inhibition of melanogenesis as an adjuvant strategy for the treatment of melanotic melanomas. 
Selective review and hypothesis. Anticancer Res 18, 3709–3716 (1998).
 75. Slominski, A., Zbytek, B. & Slominski, R. Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes 
against melanoma cells. Int J Cancer 124, 1470–1477 (2009).
 76. Slominski, A., Tobin, D. J., Shibahara, S. & Wortsman, J. Melanin pigmentation in mammalian skin and its hormonal regulation. 
Physiol Rev 84, 1155–1228 (2004).
 77. Slominski, A., Zmijewski, M. & Pawelek, J. L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte 
functions. Pigment Cell Melanoma Res 25, 14–27 (2012).
 78. Edge, S., Byrd, D. & Compton, C. Malignant melanoma of the uvea. AJCC Cancer Staging Manual. Springer: New York, USA, pp. 
547–559 (2010).
 79. Brozyna, A. A., Jozwicki, W., Carlson, J. A. & Slominski, A. T. Melanogenesis affects overall and disease-free survival in patients with 
stage III and IV melanoma. Hum Pathol 44, 2071–4, https://doi.org/10.1016/j.humpath.2013.02.022 (2013).
Acknowledgements
This study was supported partially by grant: 2012/07/B/NZ4/01657 from Polish National Science Centre to KU. 
This study was supported in part by grant 2014/15/B/NZ4/00751 from National Science Centre, Poland to AAB. 
Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University is a partner of the Leading 
National Research Center (KNOW) supported by the Ministry of Science and Higher Education. Partial support 
from NIH grants 1R01AR071189-01A1 and R01AR073004 and VA merit grant (no. 1I01BX004293-01A1) to 
ATS is also acknowledged. AMJ research was supported by the Intramural Research Program of the NIEHS, NIH 
Z01-ES-101586. Partial support to ME was given by Horizon2020 grant UMCure2020 no 667787.
Author Contributions
Anna Markiewicz prepared text of the publication, described the clinical aspects, performed literature search 
and statistical analysis, Anna A. Brożyna performed immunohistochemistry and contributed to writing of the 
manuscript, Ewa Podgórska performed immunohistochemistry, Martyna Elas managed the references, corrected 
the text, and performed literature research, Anton M. Jetten prepared antibodies for RORs and contributed to 
writing of the manuscript, Krystyna Urbańska, Andrzej T. Słominski and Bożena Romanowska-Dixon delineated 
the concept of the study and contributed to writing of the manuscript, Wojciech Jóźwicki outlined concept of the 
paper, Jolanta Orłowska-Heitzman and Grzegorz Dyduch prepared histopathological materials.
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
